"From late 2020 to the summer of 2024, Eli Lilly & Co. ( NYSE: LLY) stock was on a tear, up more than 635%, before taking a breather and then heading higher. The past couple of years have been a transformative time for the Indianapolis-based pharmaceutical giant, with substantial financial growth driven by its innovative medicines and GLP-1 drugs, significant regulatory successes, and continued investment in its pipeline and manufacturing capabilities."
"Now, the share price is 24.8% higher than six months ago, despite a retreat in the past week. In the past month, Lilly announced successful Phase 3 trial results for its retatrutide weight-loss drug, and it announced a plan to invest over $6 billion in a new manufacturing facility in Huntsville, Alabama. Earlier, it posted robust third-quarter earnings and announced a 15% dividend increase and a partnership with AI chipmaker Nvidia Corp. ( NASDAQ: NVDA)."
Eli Lilly's stock rose dramatically from late 2020 through summer 2024 and continued higher with a 24.8% six‑month gain despite recent short-term retreats. Revenue and net income growth has been driven by GLP‑1 therapies and other innovative medicines, regulatory approvals, and sustained investment in pipeline and manufacturing capacity. Recent milestones include successful Phase 3 retatrutide results, a planned $6+ billion Alabama facility, strong third‑quarter earnings, a 15% dividend increase, and a partnership with Nvidia. Operational challenges include meeting overwhelming demand and facing intense competition in the weight‑loss market. Projections use revenue and net income assumptions to estimate stock prices for 2025–2030.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]